Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gil

Showing results (21-30 of 163) with videos related to

Pageof 17
Sort By:
JAMA Oncology|February 10, 2022
Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung CancerManuel David Gil-Sierra, María Del Pilar Briceño-Casado, Marina Sánchez-Hidalgo
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 25, 2026
Methodological interpretation of subgroup analysis by histological subtype for perioperative toripalimab in resectable non-small-cell lung cancerManuel David Gil-Sierra, Elisa Pizarro-Barron, Maria Del Pilar Briceño-Casado
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|August 28, 2020
Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term dataManuel David Gil-Sierra, Esmeralda Ríos-Sánchez, María Del Pilar Briceño-Casado
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|December 15, 2022
Patient benefit as a goal of humanizationManuel David Gil-Sierra, María Del Pilar Briceño-Casado, Eduardo López-Briz
JAMA Oncology|December 26, 2024
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B DysfunctionManuel David Gil-Sierra, María Del Pilar Briceño-Casado, Cristina Moreno-Ramos
JAMA Oncology|September 7, 2023
Biomarker Analysis of Vistusertib Plus Paclitaxel RegimenManuel David Gil-Sierra, María Del Pilar Briceño-Casado, Cristina Moreno-Ramos
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 14, 2022
Clinical and pharmacoeconomic impact of subgroup analysis in onco-hematological patientsManuel David Gil-Sierra, Maria Del Pilar Briceño-Casado, Marina Sánchez-Hidalgo
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|November 27, 2024
Clinical decision making on retreatment with monoclonal antibodies in chronic/episodic migraineManuel David Gil-Sierra, Maria Del Pilar Briceño-Casado, Cristina Moreno-Ramos
Scientific Reports|November 13, 2025
Structure of a barrel-stave pore formed by magainin-2 reveals anion selectivity and zipper-mediated assemblyEnea Sancho-Vaello, Harun Kücükyildiz, David Gil-Carton, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|July 1, 2025
Immunotherapy in advanced endometrial cancer with microsatellite instability: A systematic reviewCristina Moreno-Ramos, Manuel David Gil-Sierra, María Del Pilar Briceño-Casado
Pageof 17

Showing results (21-30 of 163) with videos related to

Sort By:
Pageof 17
JAMA Oncology|February 10, 2022
Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung CancerManuel David Gil-Sierra, María Del Pilar Briceño-Casado, Marina Sánchez-Hidalgo
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 25, 2026
Methodological interpretation of subgroup analysis by histological subtype for perioperative toripalimab in resectable non-small-cell lung cancerManuel David Gil-Sierra, Elisa Pizarro-Barron, Maria Del Pilar Briceño-Casado
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|August 28, 2020
Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term dataManuel David Gil-Sierra, Esmeralda Ríos-Sánchez, María Del Pilar Briceño-Casado
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|December 15, 2022
Patient benefit as a goal of humanizationManuel David Gil-Sierra, María Del Pilar Briceño-Casado, Eduardo López-Briz
JAMA Oncology|December 26, 2024
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B DysfunctionManuel David Gil-Sierra, María Del Pilar Briceño-Casado, Cristina Moreno-Ramos
JAMA Oncology|September 7, 2023
Biomarker Analysis of Vistusertib Plus Paclitaxel RegimenManuel David Gil-Sierra, María Del Pilar Briceño-Casado, Cristina Moreno-Ramos
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 14, 2022
Clinical and pharmacoeconomic impact of subgroup analysis in onco-hematological patientsManuel David Gil-Sierra, Maria Del Pilar Briceño-Casado, Marina Sánchez-Hidalgo
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|November 27, 2024
Clinical decision making on retreatment with monoclonal antibodies in chronic/episodic migraineManuel David Gil-Sierra, Maria Del Pilar Briceño-Casado, Cristina Moreno-Ramos
Scientific Reports|November 13, 2025
Structure of a barrel-stave pore formed by magainin-2 reveals anion selectivity and zipper-mediated assemblyEnea Sancho-Vaello, Harun Kücükyildiz, David Gil-Carton, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|July 1, 2025
Immunotherapy in advanced endometrial cancer with microsatellite instability: A systematic reviewCristina Moreno-Ramos, Manuel David Gil-Sierra, María Del Pilar Briceño-Casado
Pageof 17